Novel Recombinant Plasma Method to Treat Bleeding Disorders
Novel Recombinant Plasma Method to Treat Bleeding Disorders
Fc-plasminogen Fusions for Improved Therapeutic Profile
Tags: Monash University, Australia, Healthcare & Lifesciences
Fc-plasminogen fusion proteins extend plasminogen's half-life up to five times, offering improved efficacy in treating bleeding disorders, rare diseases, and enhancing wound healing processes. This innovation arises from novel recombinant production methods in mammalian systems, overcoming previous limitations in plasminogen therapy. Applications include treating diabetic wounds, burns, and conditions with fibrin accumulation. The technology is in the lead optimization stage, aiming for broader therapeutic use.
IP Type or Form Factor: Patent Pending; Process & Method; Material; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
